Who makes Genvoya Crushed Dose?

Genvoya Crushed Dose is developed by Johns Hopkins University.

What development phase is Genvoya Crushed Dose in?

Genvoya Crushed Dose is FDA-approved (marketed).

What are the side effects of Genvoya Crushed Dose?

Common side effects include Nausea, Diarrhea, Headache, Elevated creatinine, Rash.

Last reviewed 2026-04-22 · How we verify

Genvoya Crushed Dose

Johns Hopkins University · FDA-approved active Small molecule

Genvoya is a fixed-dose combination antiretroviral that inhibits HIV reverse transcriptase and integrase to suppress viral replication.

Genvoya is a fixed-dose combination antiretroviral that inhibits HIV reverse transcriptase and integrase to suppress viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in adolescents and children (weight-based dosing).

At a glance

Generic name	Genvoya Crushed Dose
Also known as	elvitegravir/cobicistat/emtricitabine/ tenofovir alafenamide
Sponsor	Johns Hopkins University
Drug class	Antiretroviral combination (integrase inhibitor + NRTI + NtRTI + booster)
Target	HIV integrase, HIV reverse transcriptase
Modality	Small molecule
Therapeutic area	Infectious Disease / Virology
Phase	FDA-approved

Mechanism of action

Genvoya contains elvitegravir (integrase inhibitor), cobicistat (CYP3A4 inhibitor/booster), emtricitabine (nucleoside reverse transcriptase inhibitor), and tenofovir alafenamide (nucleotide reverse transcriptase inhibitor). The combination targets multiple steps of HIV replication: integrase catalyzes viral DNA integration into the host genome, while reverse transcriptase inhibitors block conversion of viral RNA to DNA. Cobicistat enhances elvitegravir bioavailability.

Approved indications

HIV-1 infection in treatment-naïve and treatment-experienced adults
HIV-1 infection in adolescents and children (weight-based dosing)

Common side effects

Nausea
Diarrhea
Headache
Elevated creatinine
Rash

Key clinical trials

Analysis of Crushed and Whole Tablet Genvoya (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Genvoya Crushed Dose CI brief — competitive landscape report
Genvoya Crushed Dose updates RSS · CI watch RSS
Johns Hopkins University portfolio CI